Impact of Comorbidities on Myocardial Remodeling and Dysfunction In Heart Failure with Preserved Ejection Fraction

Heerebeek, Loek van; Paulus, Walter J.

doi:10.15226/2374-6866/1/2/00112

Cited by 7 publications

(7 citation statements)

References 240 publications

(251 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Myocardial remodelling and dysfunction in HFpEF include myocardial hypertrophy as well as progressive myocardial fibrosis and increased cardiomyocyte stiffness. These characteristics result from specific changes in transcriptional and post-translational modifications of a huge, elastic sarcomeric protein named titin [ 22 – 26 ]. Extracellular matrix accumulation and fibrosis are often described, and may significantly contribute to impaired LV filling, a hallmark of the disease [ 27 ].…”

Section: Introductionmentioning

confidence: 99%

Biomarkers, myocardial fibrosis and co-morbidities in heart failure with preserved ejection fraction: an overview

Michalska-Kasiczak¹,

Bielecka‐Dąbrowa²,

Haehling³

et al. 2018

aoms

View full text Add to dashboard Cite

The prevalence of heart failure with preserved ejection fraction (HFpEF) is steadily increasing. Its diagnosis remains difficult and controversial and relies mostly on non-invasive echocardiographic detection of left ventricular diastolic dysfunction and elevated filling pressures. The large phenotypic heterogeneity of HFpEF from pathophysiologic al underpinnings to clinical manifestations presents a major obstacle to the development of new therapies targeted towards specific HF phenotypes. Recent studies suggest that natriuretic peptides have the potential to improve the diagnosis of early HFpEF, but they still have significant limitations, and the cut-off points for diagnosis and prognosis in HFpEF remain open to debate. The purpose of this review is to present potential targets of intervention in patients with HFpEF, starting with myocardial fibrosis and methods of its detection. In addition, co-morbidities are discussed as a means to treat HFpEF according to cut-points of biomarkers that are different from usual. Biomarkers and approaches to co-morbidities may be able to tailor therapies according to patients’ pathophysiological needs. Recently, soluble source of tumorigenicity 2 (sST2), growth differentiation factor 15 (GDF-15), galectin-3, and other cardiac markers have emerged, but evidence from large cohorts is still lacking. Furthermore, the field of miRNA is a very promising area of research, and further exploration of miRNA may offer diagnostic and prognostic applications and insight into the pathology, pointing to new phenotype-specific therapeutic targets.

show abstract

Section: Introductionmentioning

confidence: 99%

Biomarkers, myocardial fibrosis and co-morbidities in heart failure with preserved ejection fraction: an overview

Michalska-Kasiczak¹,

Bielecka‐Dąbrowa²,

Haehling³

et al. 2018

aoms

View full text Add to dashboard Cite

show abstract

“…Indeed, we removed the age factor using the Ancova test and showed that max LAVi, min LAVi and preA LAVi were still higher in patients compared to healthy controls, regardless of age. We can explain this situation as the presence of comorbidities such as hipertension, diabetes, and coronary artery disease, may cause an increase in LA volumetric functional parameters by increasing left ventricular stiffness depending on fibrosis, increased collagen and calcium deposition in the early period or by disrupting its contraction or its relaxation regardless of age [18].…”

Section: Discussionmentioning

confidence: 99%

Yüksek sol atriyal hacim indeksi ve diyastolik disfonksiyonunda sol atriyum fonksiyonel parametrelerindeki değişiklikler

Özen¹,

Sanlialp²,

Şenol³

et al. 2021

Pamukkale Medical Journal

View full text Add to dashboard Cite

show abstract

“…Age, female sex, hypertension, and obesity are all associated with HFPEF, and these factors have been implicated mechanistically as causative factors. 23 Heart failure with preserved EF is frequently associated with comorbidities, including hypertension (60%-80%), ischaemic heart disease (35%-70%), diabetes (20%-45%), and atrial fibrillation (15%-40%). There are ethnic differences in readmission rates for HFPEF, with higher rates of readmission among black patients, despite lower mortality rates – the so-called mortality readmission paradox.…”

Section: Risk Factors For Pathogenesis and Hospitalisationmentioning

confidence: 99%

Hospitalisation in Patients With Heart Failure With Preserved Ejection Fraction

Nanayakkara

Patel

Kaye

2018

Clin Med Insights Cardiol

View full text Add to dashboard Cite

Heart failure is highly prevalent with more than 50% of cases being patients with a preserved ejection fraction (HFPEF), a figure that is projected to increase due to the changing risk factor landscape, in particular the ageing population. Overall mortality is similar to patients with heart failure with reduced ejection fraction (HFREF), as are the rates of hospitalisation. Patients with HFPEF have more comorbid conditions with fewer therapeutic options available. In this review, we explore the epidemiology of hospitalisation of HFPEF, the impact of current treatment modalities, and the potential of future therapies.

show abstract

Impact of Comorbidities on Myocardial Remodeling and Dysfunction In Heart Failure with Preserved Ejection Fraction

Cited by 7 publications

References 240 publications

Biomarkers, myocardial fibrosis and co-morbidities in heart failure with preserved ejection fraction: an overview

Biomarkers, myocardial fibrosis and co-morbidities in heart failure with preserved ejection fraction: an overview

Yüksek sol atriyal hacim indeksi ve diyastolik disfonksiyonunda sol atriyum fonksiyonel parametrelerindeki değişiklikler

Hospitalisation in Patients With Heart Failure With Preserved Ejection Fraction

Contact Info

Product

Resources

About